Sinovac Biotech logo

SVA - Sinovac Biotech News Story

$6.47 0.0  0.0%

Last Trade - 22/02/19

Sector
Healthcare
Size
Micro Cap
Market Cap £n/a
Enterprise Value £n/a
Revenue £190.3m
Position in Universe th / 6854

100 mln doses of China Sinopharm's COVID-19 vaccines supplied globally

Fri 26th March, 2021 2:24pm
BEIJING, March 26 (Reuters) - Two COVID-19 vaccines
developed by subsidiaries of China National Pharmaceutical Group
(Sinopharm) have hit a combined 100 million doses of supply
around the world, a Sinopharm affiliate said late on Friday.
    Over 80 million doses of the two vaccines were administered,
China National Biotec Group Company (CNBG) said on social media.
    Sinopharm had said it could reach an annual capacity of 1
billion doses in 2021 and aims to expand capacity to 3 billion
doses per year, without specifying the timeframe for the target.
    Another Chinese vaccine maker Sinovac Biotech  SVA.O  said
on Monday it had supplied 160 million doses of its COVID-19
vaccine to 18 countries and regions, including China, with over
70 million shots injected.  urn:newsml:reuters.com:*:nP8N2LE02M
    The three vaccines, along with a fourth vaccine from CanSino
Biologics Inc  6185.HK , have been approved in China for general
public use. A fifth vaccine developed by the Institute of
Microbiology Chinese Academy of Sciences has gained clearance
for limited emergency use. 
    
    
    

 (Reporting by Roxanne Liu and Ryan Woo, editing by Louise
Heavens)
 ((hongkong.newsroom@thomsonreuters.com; (8610)6627-1277;
Reuters Messaging: roxanne.liu@thomsonreuters.com))
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.